A new study in @JAMAOnc, led by @LovaSunMD & @CharuAggarwalMD, suggests that a 2-year immunotherapy duration is reasonable for advanced #lungcancer, and indefinite immunotherapy is not associated with improved survival. #NSCLC #ASCO23 t.co/sYzlhR39to